Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

Moffitt is using their own in silico prediction methods to identify neoantigen reactive TIL, which is important [1]. We also know there is a lot of data showing that responses to checkpoint inhibitors (anti-PD-1 [2], anti-CTLA-4 [3] and anti-PD-L1 [4]) occur in patients with pre-existing neoantigen-specific T-cells in tumours.

Previous data (presented at SITC '19) can be found here [5].

Refs:
1 https://journals.lww.com/immunotherapy-journal/Abstract/2010/11000/Selection_of_CD8_PD_1__Lymphocytes_in_Fresh_Human.4.aspx
2 https://www.nature.com/articles/nature13954
3 https://ascopubs.org/doi/full/10.1200/JCO.2012.47.7521
4 https://www.nature.com/articles/nature13904
5 https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=12669&CONF=SITC19&ssoOverride=OFF&CKEY=